Orthocell boss Paul Anderson said the Murdoch-based biotech medical company is “well ahead” of its original targets in relation to US sales of its nerve repair product, Remplir.
09/05/2025 - 14:28
Orthocell heartened by US progression
09/05/2025 - 14:28
